Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream ...(the identified bacteria were reporteddir...),Health

Date:7/15/2008

the identified bacteria were reported directly to the treating clinicians whereas for patients in the Usual Care group, data were entered into the hospital's laboratory information system as usual. Medical records of enrolled patients were analyzed for demographics, comorbid conditions, location within the hospital, antimicrobial use, length of hospitalization, mortality, and other factors to understand the impact of the rapid PNA FISH results on patient care and outcomes. Significant comparison results for the two groups are listed below.

Comparison of Data for Notification of PNA FISH (NPF) group vs. Usual Care (UC) group

-- Total of 202 patients enrolled in study; 101 in NPF group vs. 101 in UC group

-- 61 patients with S. aureus; 32 in NPF group vs. 29 in UC group

-- 141 patient with CoNS; 69 in NPF vs. 72 in UC group

-- 44 patients in ICU vs. 158 in non-ICU

-- 53% reduction in overall mortality; 8 deaths in NPF group vs. 17 deaths in UC group

-- 80% reduction in mortality rate for intensive care unit (ICU) patients; 10% (2 deaths) for NPF group vs. 48% (11 deaths) for UC group

-- 82% reduction in mortality rate for ICU patients with S. aureus; 10% for NPF group vs. 56% for UC group

-- 67% reduction in median antibiotic use after notification of results; median of 1 day for NPF group vs. 3 days for UC group

-- 100% reduction in median antibiotic use for CoNS patients after notification of; 0 days for NPF group vs. 2.5 days for UC group

-- Trend toward $19,441 reduction in median hospital charges; $72,932 median charges for NPF group vs. $92,373 for UC group

"Rapid delivery of PNA FISH data from the laboratory to treating clinicians was associated with reduced mortality in ICU patients," said lead author Shmuel Shoham, M.D., Section of Infectious Diseases and Director of Transplant Infectious Diseases at Washington Hospital Center. "There was also a trend toward reduced length of
'/>"/>

SOURCE AdvanDx Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
2. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
5. Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU
6. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
7. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
8. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease